Clinical evaluation of formula F105, designed and developed to address elevated oxidized LDL Cholesterol (oxLDL) levels

In 2012, it is estimated that 17.5 million people died from cardiovascular disease (CVD) globally.¹ Meta-analysis reveals that for every 1% reduction in cholesterol an estimated 2.5% reduction in coronary heart disease;² in addition emerging science has shown oxLDL to be the most significant predictor of a future cardiac event.³ In a 12-week open-label clinical study of F105, 8 subjects saw the following changes to major cardiovascular risk factors without dietary intervention or weight loss:

	Median Change	Median % Change	P value*	Hazard Ratio (95% CI)3
Total Cholesterol	-23	-10	0.008	1.20 (0.93 – 1.56)
LDL	-21	-10	0.031	1.90 (1.44 – 2.51)
Triglycerides	-35	-27	0.039	2.34 (1.79 – 3.05)
Cholesterol/HDL	-2.5	-45	0.016	6.12 (4.56 – 8.20)
oxLDL	-14	-19	0.047	8.26 (6.15 – 11.11)
oxLDL/HDL	-0.3	-25	0.039	13.92 (10.07 – 19.23)
* P-values were computed using the log-normal distribution of the ratio of change from baseline to 12 weeks using a Wilcoxon Signed Rank test of the median against the null hypothesis.

[1] WHO.int -Cardiovascular Diseases, Fact Sheet No 317.; [2] Holme I. Circulation 1990; 82:1916 – 1924.; [3] Johnston, N. et al. Am. J. Cardiol. 2006, 97: 640 – 645.